Argent Biopharma Ltd RGT
ASX · Australia · Health Technology
AUD 0.0300-0.00 (-6.25%)
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Initial tranche assists CannEpil® development and commercialization Financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines FORT LAUDERDALE, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (NYSE American: EDVA) (“Endovia” or the “Company”), a cannabinoid health sciences company, today announced that it has closed initial funding from C/M Capital Master Fund, LP (“C/M Capital”), represe
The company secured an exclusive global licensing agreement for CannEpil.
Splash Beverage Group, Inc. (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT) (LSE: RGT) for CannEpil®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.